VLX-1005

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H19N3O4S2
Molecular Weight	441.523
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=C(O)C(CNC2=CC=C(C=C2)S(=O)(=O)NC3=NC4=C(S3)C=CC=C4)=CC=C1

InChI

InChIKey=OWHBVKBNNRYMIN-UHFFFAOYSA-N

InChI=1S/C21H19N3O4S2/c1-28-18-7-4-5-14(20(18)25)13-22-15-9-11-16(12-10-15)30(26,27)24-21-23-17-6-2-3-8-19(17)29-21/h2-12,22,25H,13H2,1H3,(H,23,24)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25506969 | http://www.bloodjournal.org/content/126/23/3442 | https://www.ncbi.nlm.nih.gov/pubmed/24393039

ML355 is a potent and selective inhibitors of 12-Lipoxygenase(12-LOX) with IC50 of 0.34 uM. It has excellent selectivity over related lipoxygenases and cyclooxygenases. ML355 has favorable absorption, distribution, metabolism, and excretion (ADME) properties, inhibits PAR-4 induced aggregation and calcium mobilization in human platelets, and reduces 12-HETE in mouse/human beta cells suggesting its potential utility in animal models for antiplatelet therapy and diabetes.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Arachidonate 12-lipoxygenase 4 Target ID: CHEMBL3687 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24393039 \| https://www.ncbi.nlm.nih.gov/pubmed/25506969	Inhibitor 8504		0.34 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Diabetes mellitus 93 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24393039 http://www.bloodjournal.org/content/126/23/3442	Primary		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Synthesis and structure-activity relationship studies of 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase.	2014-01-23	24393039

Sample Use Guides

In Vivo Use Guide

Mice: In vivo PK studies where ML355 was administered as a solution via IV (3mg/kg) and PO (30mg/kg) demonstrated that ML355 is orally bioavailable (%F = 20) with good half-life (T1/2 = 2.9 hours).

Route of Administration: Other

In Vitro Use Guide

ML355 was able to potently inhibit 12-HETE in BTC3 cells with an approximate IC50 of 1 uM, as measured by ELISA. At concentrations as low as 250 nM of ML355 calcium mobilization in human platelets is reduced significantly (measured as fold change), with complete inhibition of calcium mobilization occurring at ∼5 uM.

Name

Type

Language

VLX-1005

Code

English

ML-355

Preferred Name

English

BENZENESULFONAMIDE, N-2-BENZOTHIAZOLYL-4-(((2-HYDROXY-3-METHOXYPHENYL)METHYL)AMINO)-

Systematic Name

English

N-2-BENZOTHIAZOLYL-4-(((2-HYDROXY-3-METHOXYPHENYL)METHYL)AMINO)BENZENESULFONAMIDE

Systematic Name

English

ML355

Code

English

Classification Tree Code System Code

FDA ORPHAN DRUG

736720